Business
RENX Admission to AIM and First Day of Dealings
RENX Admission to AIM and First Day of Dealings.
About this update from Renalytix Plc
[{"type":"text","content":"\n \nRNS Number : 4152G Renalytix AI PLC 06 November 2018 \n\nRenalytix AI plc\n(\"RenalytixAI\" or the \"Company\") \n \nAdmission to trading on AIM and First Day of Dealings\nTotal funds raised of £22.25m \n \nRenalytix AI plc (AIM: RENX), a developer of artificial intelligence (\"AI\") enabled clinical diagnostic solutions for kidney disease, announces the admission of its ordinary shares (\"Ordinary Shares\") to trading on AIM (\"Admission\"). Dealings in the Ordinary Shares will commence today under the ticker \"RENX\" and ISIN GB00BYWL4Y04. \n \nThe Company's Admission Document is available from www.renalytixai.com/investors\n \nTransaction highlights\n· £22.25 million raised through a placing, US subscription and restricted offer to shareholders of EKF Diagnostics Holdings plc (\"EKF\") (the \"Fundraising\") at a price £1.21 per Ordinary Share (the \"Issue Price\")\n· 53,816,134 Ordinary Shares in issue at Admission\n· The Ordinary Shares issued in connection with the Fundraising represent c. 34.2% of the enlarged share capital of the Company at Admission\n· £65.12 million market capitalisation on Admission at the Issue Price\n· N+1 Singer acted as placing agent and is retained as Nominated Adviser and Broker to RenalytixAI\n \nAbout RenalytixAI\nRenalytixAI is a pioneering developer of AI-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.\n \nRenalytixAI's technology platform will draw from distinct sources of data, including systems containing extensive de-identified electronic health records (\"EHR\"), predictive blood-based biomarkers and other genomic information for analysis by high-performance, learning computer algorithms (machine learning). RenalytixAI intends to build a deep, unique pool of kidney disease-related data for AI-enabled applications designed to improve predictive capability and clinical utility over time.\n \nIn May 2018, RenalytixAI secured a cornerstone collab...